Orion Oyj (OTCMKTS:ORINF) Short Interest Down 19.1% in December

Orion Oyj (OTCMKTS:ORINF) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 488,600 shares, a decline of 19.1% from the November 30th total of 604,200 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 4,886.0 days.

Orion Oyj Stock Performance

Shares of ORINF remained flat at $48.65 during trading hours on Friday. Orion Oyj has a twelve month low of $48.65 and a twelve month high of $48.65. The stock has a 50 day moving average of $47.82 and a 200-day moving average of $47.39.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.